EE438 A Budget Impact Model (BIM) for the Introduction of the TEARCARE® System to a United States (US) Health Plan for the Treatment of Meibomian Gland Dysfunction (MGD)-Associated Dry Eye Disease (DED)
THERAPY FOR DRY EYE (DE) AND MEIBOMIAN GLAND DYSFUNCTION (MGD) BASED ON THE REPLACEMENT OF O-ACYL-Ω-HYDROXY FATTY ACIDS (OAHFA)